500 RIVER RIDGE DRIVE, NORWOOD, MA
Announces Pricing of Public Offering
Other Events
Investor Presentation
FDA Grants Fast Track Designation to Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Material disclosure
Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Annual Report to Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Q2
Q1
FY 2024
Q3
FY 2023 amended
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Additional Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Registration of Securities under Section 12(g)